| Name | Title | Contact Details |
|---|
biOasis Technologies Inc., an early stage biopharmaceutical company, engages in the research, development, and commercialization of technologies and products for the diagnosis and treatment of central nervous system diseases and disorders. The company develops Transcend program, a protein vector, which is a proprietary carrier for the transport of therapeutic agents across the blood brain barrier for treatment of a range of neurological, oncological, and infectious disease applications; and Cognitest, a proprietary in vitro diagnostic assay for Alzheimer’s disease. It has a collaborative research agreement with the University of British Columbia to assist the company in development of an enzyme linked immunosorbent assay to detect levels of p97 in blood for the purpose of evaluating the correlation between p97 and Alzheimer’s disease. The company was incorporated in 2006 and is headquartered in Vancouver, Canada.
Empowering the industry with the resources, expertise, and capital to help accelerate the advancement and adoption of cell and gene therapies.
Agena Bioscience’s scalable MassARRAY System enables one day assay turnaround times on a wide variety of targeted genetic tests.
ALX Oncology is a clinical stage biotechnology company developing innovative immuno-oncology therapies for cancer.
Practical Applications is a Boston, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.